Britt K Erickson1, Burak Zeybek2, Alessandro D Santin2, Amanda N Fader3. 1. Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota. 2. Division of Gynecologic Oncology, Yale University, New Haven, Connecticut. 3. Division of Gynecologic Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers. RECENT FINDINGS: Approximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated. SUMMARY: HER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.
PURPOSE OF REVIEW: The purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers. RECENT FINDINGS: Approximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated. SUMMARY: HER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.
Authors: P Todeschini; E Cocco; S Bellone; J Varughese; K Lin; L Carrara; F Guzzo; N Buza; P Hui; D-A Silasi; E Ratner; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin Journal: Br J Cancer Date: 2011-09-13 Impact factor: 7.640
Authors: C L Schwab; S Bellone; D P English; D M Roque; S Lopez; E Cocco; R Nicoletti; I Bortolomai; E Bonazzoli; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; A D Santin Journal: Br J Cancer Date: 2014-09-30 Impact factor: 7.640
Authors: Alexandra Canonici; Merel Gijsen; Maeve Mullooly; Ruth Bennett; Noujoude Bouguern; Kasper Pedersen; Neil A O'Brien; Ioannis Roxanis; Ji-Liang Li; Esther Bridge; Richard Finn; Dennis Siamon; Patricia McGowan; Michael J Duffy; Norma O'Donovan; John Crown; Anthony Kong Journal: Oncotarget Date: 2013-10
Authors: David M Hyman; Sarina A Piha-Paul; Helen Won; Jordi Rodon; Cristina Saura; Geoffrey I Shapiro; Dejan Juric; David I Quinn; Victor Moreno; Bernard Doger; Ingrid A Mayer; Valentina Boni; Emiliano Calvo; Sherene Loi; Albert C Lockhart; Joseph P Erinjeri; Maurizio Scaltriti; Gary A Ulaner; Juber Patel; Jiabin Tang; Hannah Beer; S Duygu Selcuklu; Aphrothiti J Hanrahan; Nancy Bouvier; Myra Melcer; Rajmohan Murali; Alison M Schram; Lillian M Smyth; Komal Jhaveri; Bob T Li; Alexander Drilon; James J Harding; Gopa Iyer; Barry S Taylor; Michael F Berger; Richard E Cutler; Feng Xu; Anna Butturini; Lisa D Eli; Grace Mann; Cynthia Farrell; Alshad S Lalani; Richard P Bryce; Carlos L Arteaga; Funda Meric-Bernstam; José Baselga; David B Solit Journal: Nature Date: 2018-01-31 Impact factor: 49.962
Authors: Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine Journal: Nature Date: 2013-05-02 Impact factor: 49.962
Authors: Matthew A Powell; Virginia L Filiaci; Martee L Hensley; Helen Q Huang; Kathleen N Moore; Krishnansu S Tewari; Larry J Copeland; Angeles A Secord; David G Mutch; Alessandro Santin; David P Warshal; Nick M Spirtos; Paul A DiSilvestro; Olga B Ioffe; David S Miller Journal: J Clin Oncol Date: 2022-01-10 Impact factor: 50.717
Authors: Katia Pane; Mario Zanfardino; Anna Maria Grimaldi; Gustavo Baldassarre; Marco Salvatore; Mariarosaria Incoronato; Monica Franzese Journal: Biomedicines Date: 2022-06-02
Authors: Arnaud Da Cruz Paula; Deborah F DeLair; Lorenzo Ferrando; Daniel J Fix; Robert A Soslow; Kay J Park; Sarah Chiang; Jorge S Reis-Filho; Ahmet Zehir; Mark T A Donoghue; Michelle Wu; David N Brown; Rajmohan Murali; Claire F Friedman; Dmitriy Zamarin; Vicky Makker; Jennifer J Mueller; Mario M Leitao; Nadeem R Abu-Rustum; Carol Aghajanian; Britta Weigelt Journal: Gynecol Oncol Date: 2021-02-21 Impact factor: 5.482